the compounding thing finally clicked for me and I want to write it down
Posting this as a discussion rather than a claim: the compounding thing finally clicked for me and I want to write it down.
Why "compounded" is not "generic", written out because the confusion is constant.
A generic is an approved product demonstrated to be bioequivalent to a reference. A compounded preparation is made for a patient or, in the case of an outsourcing facility, under a different regulatory route entirely. It carries no equivalence claim and it is not required to demonstrate one.
That is not a quality judgement. Plenty of compounded preparations are made carefully in facilities with real testing programmes. It is a statement about what has and has not been established, and the difference matters when people assume the two are interchangeable.
The five questions worth asking before you commit to any compounded arrangement.
Which facility, by name. Whether it is a 503A pharmacy or a 503B outsourcing facility. What concentration is on the label. What the beyond-use date is based on. Whether there is potency testing on the finished preparation rather than only on the starting material.
All five are answerable in one email and the pattern of what comes back is more informative than any of the individual answers. An organisation with a quality system finds these questions ordinary.
Asked for potency testing on the finished preparation. They had it. I had assumed they would not.
Would rather be corrected in public than confident in private.
best — the order this archive was captured in
Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number on the label.
503A is patient-specific, 503B is outsourcing facility, they are not the same thing
[deleted]
What did the intake actually ask you?
Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.
Agreed. The 503A versus 503B distinction changes who is allowed to make what, and almost every confused thread here starts by ignoring it.
A beyond-use date derived from published stability data means something different from one assigned by default rule. Asking which is a fair question and the answer is usually available.
Asked which facility and got a name straight away. Looked it up, found the registration, felt considerably better about the whole thing.
Small fix — 503B facilities register with the regulator; 503A pharmacies are licensed by the state board. Different mechanisms.
Correction: patient-specific refers to the prescription, not to a bespoke formulation. Common misreading and it changes the argument.
shortage status changes and the whole arrangement changes with it
Yes. The shortage list is the legal hinge for the whole arrangement and its status is public.
the pharmacy and the prescriber are two separate questions
the shortage list is the whole legal hinge and people skip it
Removed the staff name. Facilities and clinics can be named here; individuals cannot.
a 503B has to register and report, so there is a paper trail to ask for
Paid noticeably more at one clinic than another for what turned out to be the same facility behind both.
compounded is not generic, there is no equivalence claim
503A or 503B — do you know which?
Was there potency testing on the finished preparation, or only on the starting material?
That figure is the starting material purity, not the finished preparation potency. Two different tests.
- 1A beyond-use date derived from published stability data means something…13 comments in this branch · started by u/bruno_dumitru
- 2Salt form matters for mass: a preparation specified as one salt and dosed as…6 comments in this branch · started by u/clara_danquah